3 studies found for:    19380866 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
2 Recruiting Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Conditions: Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide;   Drug: Etoposide;   Drug: Alemtuzumab;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Rituximab;   Drug: Vincristine
3 Completed
Has Results
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
Condition: B-Cell Lymphoma
Interventions: Drug: PS-341;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Filgrastim

Indicates status has not been verified in more than two years